Boehringer Ingelheim buys Pharmaxis NASH candidate
This article was originally published in Scrip
Boehringer Ingelheim is to pay €27.5m up front plus upwards of €500m in milestones to acquire a Phase I candidate that has shown preclinical promise in non-alcoholic steatohepatitis (NASH) from Pharmaxis. The German company is exercising an option that it already held to acquire the investigational drug PXS4728A, a semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor that is designed to block leucocyte adhesion and tissue infiltration in inflammatory processes.
You may also be interested in...
With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.
OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies
Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.
NPA asks Congress to include supplements in legislation defining "medical expenses” covered by pre-tax health savings accounts. The trade group says industry would prefer supplements were included with OTC drugs in provision in recently passed COVID-19 relief legislation that changed pre-tax account rules.